It's no secret Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares had an awful Tuesday. In the afternoon, ex-pharma exec-turned hedge fund manager-turned FBI fraud target Martin Shkreli analyzed the company on his YouTube channel.
According to several tweets recapping the episode, Shkreli valued Valeant at about $28.37 per share. He also added that he doesn't think Valeant is worth shorting, according to Twitter.
Additionally, files publicly shared by Shkreli suggest he's forecasting a gross margin decline for Valeant from 77 percent in 2016 to 70 percent by 2025.
Valeant shares closed Tuesday at $33.54. They were above $200 a year ago.
The live stream is still rolling, below.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
